All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 5 read as filed from the record and 4 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2017; the latest 2020-04-24.
From the record
Larimar Therapeutics, Inc.'s filings since 2017 show 2 warning events: a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2020-04-24) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
8 filed years; profitable in 0 of 4.
From the record
Larimar Therapeutics, Inc.'s 8 filed years say what it did: it never fell from a peak; net income was positive in 0 of 4 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 5.8/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Larimar Therapeutics, Inc.'s shareholder treatment is put at 5.8 of 10 with a confidence of 20 of 100, because fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income, so the desk assumes the typical reading of its industry family, the median of 295 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -212%: lost 212¢ per shareholder dollar. Leverage 46%: owes 46¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Larimar Therapeutics, Inc. lost about 212 cents for every dollar of shareholders' money. Leverage: it owed about 46 cents per dollar of assets (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
SI estimate 5.2/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Larimar Therapeutics, Inc.'s industry position is put at 5.2 of 10 with a confidence of 20 of 100, because no filed revenue on file, so the desk assumes the typical reading of its industry family, the median of 315 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are the people in charge doing?
top 27% of 315 in its family for leadership; chief executive since 2020.
From the record
Larimar Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Ben-Maimon, Carole (President and CEO, as filed), filing under that title since 2020-06-05, 6.4 years (top 33% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 6.4 years (top 34%); 2 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (top 14%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
SI estimate 7.2/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Larimar Therapeutics, Inc.'s room to expand is put at 7.2 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the top 28% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.
What could actually drive growth from here?
top 23% of 306 in its family for growth drivers.
From the record
Larimar Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2019: research spending grew 85.2% a year (top 4%); capital spending grew -3.1% a year (top 42%) (its annual reports). Larimar Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
SI estimate 7.2/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Larimar Therapeutics, Inc.'s expectations vs reality is put at 7.2 of 10 with a confidence of 35 of 100, because read from one part only, net income against the prior three years' average, which ranks in the top 28% of 284 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change. A filing that carries the missing parts replaces this estimate with the filed reading.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made